These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 29487979)
1. The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models. Läubli H; Müller P; D'Amico L; Buchi M; Kashyap AS; Zippelius A Cancer Immunol Immunother; 2018 May; 67(5):815-824. PubMed ID: 29487979 [TBL] [Abstract][Full Text] [Related]
2. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843 [TBL] [Abstract][Full Text] [Related]
3. Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion. Du Four S; Maenhout SK; Benteyn D; De Keersmaecker B; Duerinck J; Thielemans K; Neyns B; Aerts JL Cancer Immunol Immunother; 2016 Jun; 65(6):727-40. PubMed ID: 27098427 [TBL] [Abstract][Full Text] [Related]
4. Folate-Hapten-Mediated Immunotherapy Synergizes with Vascular Endothelial Growth Factor Receptor Inhibitors in Treating Murine Models of Cancer. Bandara NA; Bates CD; Lu Y; Hoylman EK; Low PS Mol Cancer Ther; 2017 Mar; 16(3):461-468. PubMed ID: 27980109 [TBL] [Abstract][Full Text] [Related]
5. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma. Lu L; Saha D; Martuza RL; Rabkin SD; Wakimoto H J Neurooncol; 2015 Jan; 121(1):91-100. PubMed ID: 25213669 [TBL] [Abstract][Full Text] [Related]
6. Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. Stehle F; Schulz K; Fahldieck C; Kalich J; Lichtenfels R; Riemann D; Seliger B J Biol Chem; 2013 Jun; 288(23):16334-16347. PubMed ID: 23625925 [TBL] [Abstract][Full Text] [Related]
12. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
13. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies. Adachi Y; Kamiyama H; Ichikawa K; Fukushima S; Ozawa Y; Yamaguchi S; Goda S; Kimura T; Kodama K; Matsuki M; Miyano SW; Yokoi A; Kato Y; Funahashi Y Cancer Res; 2022 Jan; 82(2):292-306. PubMed ID: 34753772 [TBL] [Abstract][Full Text] [Related]
15. Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner. Morelli MB; Amantini C; Nabissi M; Cardinali C; Santoni M; Bernardini G; Santoni A; Santoni G Oncotarget; 2017 Jan; 8(2):3380-3395. PubMed ID: 27926485 [TBL] [Abstract][Full Text] [Related]
16. Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Kelly RJ; Rixe O Target Oncol; 2009 Dec; 4(4):297-305. PubMed ID: 19876699 [TBL] [Abstract][Full Text] [Related]
17. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma. Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280 [TBL] [Abstract][Full Text] [Related]
18. Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy. Lan J; Li R; Yin LM; Deng L; Gui J; Chen BQ; Zhou L; Meng MB; Huang QR; Mo XM; Wei YQ; Lu B; Dicker A; Xue JX; Lu Y Int J Radiat Oncol Biol Phys; 2018 May; 101(1):74-87. PubMed ID: 29619980 [TBL] [Abstract][Full Text] [Related]
19. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice. Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591 [TBL] [Abstract][Full Text] [Related]
20. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma. Zakharia Y; Zakharia K; Rixe O Expert Opin Drug Discov; 2015; 10(8):925-35. PubMed ID: 26039031 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]